vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
RE/MAX Holdings, Inc. is the larger business by last-quarter revenue ($71.1M vs $38.3M, roughly 1.9× ImmunityBio, Inc.). RE/MAX Holdings, Inc. runs the higher net margin — 2.0% vs -161.8%, a 163.8% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
IBRX vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $71.1M |
| Net Profit | $-61.9M | $1.4M |
| Gross Margin | 99.0% | — |
| Operating Margin | -169.0% | 13.1% |
| Net Margin | -161.8% | 2.0% |
| Revenue YoY | 407.0% | -1.8% |
| Net Profit YoY | -4.7% | -75.2% |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $71.1M | ||
| Q3 25 | $32.1M | $73.2M | ||
| Q2 25 | $26.4M | $72.8M | ||
| Q1 25 | $16.5M | $74.5M | ||
| Q4 24 | $7.6M | $72.5M | ||
| Q3 24 | $6.1M | $78.5M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | — | $78.3M |
| Q4 25 | $-61.9M | $1.4M | ||
| Q3 25 | $-67.3M | $4.0M | ||
| Q2 25 | $-92.6M | $4.7M | ||
| Q1 25 | $-129.6M | $-2.0M | ||
| Q4 24 | $-59.2M | $5.8M | ||
| Q3 24 | $-85.7M | $966.0K | ||
| Q2 24 | — | $3.7M | ||
| Q1 24 | — | $-3.4M |
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -169.0% | 13.1% | ||
| Q3 25 | -173.5% | 25.0% | ||
| Q2 25 | -269.8% | 19.3% | ||
| Q1 25 | -390.1% | 7.2% | ||
| Q4 24 | -919.0% | 5.9% | ||
| Q3 24 | -1314.3% | 19.4% | ||
| Q2 24 | — | 20.6% | ||
| Q1 24 | — | 5.8% |
| Q4 25 | -161.8% | 2.0% | ||
| Q3 25 | -209.8% | 5.4% | ||
| Q2 25 | -350.3% | 6.4% | ||
| Q1 25 | -784.9% | -2.6% | ||
| Q4 24 | -783.4% | 8.0% | ||
| Q3 24 | -1404.0% | 1.2% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | -4.3% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $-0.07 | — | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $-0.08 | — | ||
| Q3 24 | $-0.14 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $-500.5M | $452.4M |
| Total Assets | $501.9M | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | $118.7M | ||
| Q3 25 | $257.8M | $107.5M | ||
| Q2 25 | $153.7M | $94.3M | ||
| Q1 25 | $61.6M | $89.1M | ||
| Q4 24 | $149.8M | $96.6M | ||
| Q3 24 | $130.4M | $83.8M | ||
| Q2 24 | — | $66.1M | ||
| Q1 24 | — | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | $-500.5M | $452.4M | ||
| Q3 25 | $-524.3M | $448.1M | ||
| Q2 25 | $-570.7M | $442.4M | ||
| Q1 25 | $-591.4M | $433.5M | ||
| Q4 24 | $-489.1M | $429.5M | ||
| Q3 24 | $-745.1M | $423.1M | ||
| Q2 24 | — | $418.4M | ||
| Q1 24 | — | $412.0M |
| Q4 25 | $501.9M | $582.5M | ||
| Q3 25 | $519.0M | $582.2M | ||
| Q2 25 | $402.1M | $574.8M | ||
| Q1 25 | $303.8M | $571.4M | ||
| Q4 24 | $382.9M | $581.6M | ||
| Q3 24 | $364.6M | $578.6M | ||
| Q2 24 | — | $571.4M | ||
| Q1 24 | — | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $40.9M |
| Free Cash FlowOCF − Capex | $-71.3M | $33.5M |
| FCF MarginFCF / Revenue | -186.2% | 47.1% |
| Capex IntensityCapex / Revenue | 2.4% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $40.9M | ||
| Q3 25 | $-68.9M | $17.7M | ||
| Q2 25 | $-79.7M | $4.6M | ||
| Q1 25 | $-85.9M | $5.7M | ||
| Q4 24 | $-85.1M | $59.7M | ||
| Q3 24 | $-98.8M | $17.6M | ||
| Q2 24 | — | $15.9M | ||
| Q1 24 | — | $9.4M |
| Q4 25 | $-71.3M | $33.5M | ||
| Q3 25 | $-69.6M | $16.4M | ||
| Q2 25 | $-80.8M | $2.9M | ||
| Q1 25 | $-87.0M | $4.0M | ||
| Q4 24 | $-87.3M | $53.0M | ||
| Q3 24 | $-101.6M | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
| Q4 25 | -186.2% | 47.1% | ||
| Q3 25 | -217.2% | 22.4% | ||
| Q2 25 | -305.9% | 4.0% | ||
| Q1 25 | -526.9% | 5.3% | ||
| Q4 24 | -1155.4% | 73.2% | ||
| Q3 24 | -1663.2% | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
| Q4 25 | 2.4% | 10.4% | ||
| Q3 25 | 2.3% | 1.8% | ||
| Q2 25 | 4.1% | 2.2% | ||
| Q1 25 | 6.8% | 2.3% | ||
| Q4 24 | 28.0% | 9.1% | ||
| Q3 24 | 45.7% | 1.7% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IBRX
Segment breakdown not available.
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
